CDNF in Amyotrophic Lateral Sclerosis
Herantis’ collaborator, the University of Helsinki, has early preclinical data suggesting possible benefits of CDNF in the treatment of ALS (Amyotrophic Lateral Sclerosis). ALS, also known as Motor Neurone Disease or Lou Gehrig’s disease, is a fatal motoneuron disease whose symptom is typically weakness of limb muscles. With disease progression the patient loses ability to control muscles causing difficulty in moving, speaking, swallowing and breathing. Average lifetime expectation from diagnosis is between two and five years. ALS cannot be cured and available treatments are essentially symptomatic. Estimated 140,000 new cases are diagnosed annually.
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) and the US Food and Drug Administration (FDA) have granted orphan drug designation for CDNF for treatment of ALS. Herantis has not started clinical development with CDNF for the treatment of ALS.